Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety to trimetazidine MR 35mg in patients with stable angina pectoris: A multicenter, double-blind, placebo-controlled study

American Journal of Cardiovascular Drugs

Volumn 3, Issue 5, 2003, Pages 361-369

  Sellier, Philippe ^a   Broustet, Jean Paul ^b  

^a HÔPITAL BROUSSAIS   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; ATENOLOL; NIFEDIPINE; NITRATE; PLACEBO; PROPRANOLOL; TRIMETAZIDINE;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLLAPSE; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DATA ANALYSIS; DEATH; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE TOLERANCE; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; STABLE ANGINA PECTORIS; STATISTICAL ANALYSIS; UNSTABLE ANGINA PECTORIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANGINA PECTORIS; DOUBLE-BLIND METHOD; EUROPE; EXERCISE TEST; FEMALE; HUMANS; ISRAEL; LATVIA; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RUSSIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 0242551492     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303050-00007     Document Type: Article

References (24)

1. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8
2. Pornin M, Harpey C, Allal J, et al. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: a placebo-controlled study. Clin Trials Metaanal 1994; 29: 49-56
3. 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987; 286: 97-110
4. El Banani H, Bernard M, Bretz D, et al. Changes in intracellular sodium and pH during ischemia reperfusion are attenuated by trimetazidine: comparison between low-flow and zero-flow ischemia. Cardiovasc Res 2000; 47: 638-96
5. Lopaschuk GD, Belke DD, Gamble J, et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994; 1213: 263-76
6. Stanley WC, Lopaschuk GD, Hall JL, et al. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: potential for pharmacological interventions. Cardiovasc Res 1997; 33: 243-57
7. Sellier P. Effets de la trimætazidine sur les paramètres ergométriques dans l'angor d'effort: etude multicentrique contrôlée à double insu contre placebo. Arch Mal Coeur Vaiss 1986; 9: 1331-6
8. Dalla Volta S, Maraglino G, Della Valentina B, et al. Comparison of trimetazidine with nifedipine in effort angina: a double blind cross over study. Cardiovasc Drugs Ther 1990; 4 Suppl. 4: 853-60
9. Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina: comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994; 37: 279-88
10. Committee for Proprietary Medicinal Products. Note for guidance on modified release oral and transdermal dosage forms: section II (pharmacokinetic and clinical evaluation) [CPMP/EWP/280/96]. The European Agency for the Evaluation of Medicinal Products (Human Medicines Evaluation Unit). London UK. 1999 July 28
11. Campeau L. Letter to the Editor. Circulation 1976; 54: 522
12. Borg GA. Psycho-physical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-87
13. Senn SJ. Testing for balance in clinical trials. Stat Med 1994; 13: 1715-26
14. Bristol DR, Castellana JV. Survival analysis techniques in angina pectoris trials. Stat Med 1990; 9: 293-9
15. Fox KM, Mulcahy D, Findlay I, et al. The Total Ischaemic Burden European Trial (TIBET): effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J 1996; 17: 96-103
16. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blinded, multicentre study (TRIMPOL II). Eur Heart J 2001; 22: 2267-74
17. Van der Wring JAFM, Daniëls MCG, Holwerda NJH, et al. Combination of calcium channel blockers and β-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Br J Clin Pharmacol 1999; 47: 493-8
18. Van Kesteren HAM, Withagen AJAM, on behalf of the Amlodipine Study Group. A comparative study of once-daily amlodipine versus twice-daily diltiazem controlled release (CR) in the treatment of stable angina pectoris. Cardiovasc Drugs Ther 1998; 12: 233-7
19. Rizzon P, Lagioia R, on behalf of the Amlodipine vs Sustained-Release Isosorbide-5-Mononitrate in Chronic Ischemia Study Group. Comparison between anti-ischemic efficacy and drug plasma levels: amlodipine versus isosorbide-5-mononitrate trial. Eur Heart J Suppl 1999; 1 Suppl. I: 118-25
20. Ardissino D, Savonitto S, Egstrup K, et al. Selection of medical treatment in stable angina pectoris: results of the International Multicentre Angina Exercise (IMAGE) study. J Am Coll Cardiol 1995; 25 (7): 1516-21
21. Willich SN, for the ESCVA Study Group. European Survey on Circadian Variation of Angina Pectoris (ESCVA): design and preliminary results. J Cardiovasc Pharmacol 1999; 34 Suppl. 2: S9-S13
22. Yusuf S, Lessem J, Jha P, et al. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens 1993; 11 Suppl. 4: S61-73
23. ACC/AHA/ACP-ASIM Guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 1999; 33 (7): 2092-197
24. Barron HV, Viskin S, Lundstrom RJ, et al. Beta-blocker dosages and mortality after myocardial infarction. Arch Intern Med 1998; 158: 449-53